Heart failure trials recruiting in Ohio

All Heart failure trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A Nurse-Led Weight Monitoring Intervention For Heart Failure Quality of LIfe and Self-Care
  NCT07184541 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female) · Ohio: Avon
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · Ohio: Cleveland, Columbus
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
  NCT05489705 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
  NCT07214376 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · Ohio: Cleveland
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Canton, Cincinnati, Cleveland, Dayton
• A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
  NCT07219511 · Phase: Phase 1 · Ages: 50 Years and older · Sex: All (male and female) · Ohio: Cleveland
• A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure
  NCT05627440 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 100 Years · Sex: All (male and female) · Ohio: Cleveland
• A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
  NCT07795814 · Phase: Phase 2 · Ages: 30 Years to 84 Years · Sex: All (male and female) · Ohio: Cincinnati
• A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
  NCT06056297 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
  NCT06024746 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Centerville
• A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
  NCT06008197 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Akron, Centerville, Cincinnati
• A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
  NCT06033950 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Akron, Centerville, Cincinnati
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus, Dayton, Maumee
• A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
  NCT06991257 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Ohio: Lima
• A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
  NCT07192952 · Phase: Phase 3 · Ages: Up to 18 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
  NCT07188805 · Phase: Phase 3 · Ages: 6 Months to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland, Marion
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Marion, Toledo
• AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
  NCT06793371 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Ohio: Cincinnati
• AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
  NCT06378632 · Phase: Not specified · Ages: 22 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)
  NCT07559903 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
  NCT06651970 · Phase: Phase 4 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Ohio: Columbus
• Alleviant ALLAY-HF Study
  NCT05685303 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Cleveland, Toledo
• Alleviant ALLAY-HFrEF Study
  NCT06812533 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland, Toledo
• Assessment of CCM in HF With Higher Ejection Fraction
  NCT05064709 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus, Toledo
• Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
  NCT07232030 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• BiVACOR® Total Artificial Heart Early Feasibility Study
  NCT06174103 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Cincinnati
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• CV Imaging of Metabolic Interventions
  NCT05650307 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
  NCT06258447 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 90 Years · Sex: All (male and female) · Ohio: Cleveland
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Development of CIRC Technologies
  NCT05654272 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Dietary Tracking in Heart Failure
  NCT07649148 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
  NCT05677100 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: All (male and female) · Ohio: Columbus
• ELEVATE-HFpEF Clinical Study
  NCT06678841 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Columbus
• Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF
  NCT06849752 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
  NCT01790152 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Ohio: Akron, Cincinnati
• Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  NCT05714085 · Phase: Phase 2, Phase 3 · Ages: 29 Days to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
  NCT04592445 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Columbus
• Fluid Guided Heart Failure Treatment at the Cleveland Clinic
  NCT07205120 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
  NCT06898515 · Phase: Phase 3 · Ages: 22 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation
  NCT06291922 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
  NCT06310031 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 100 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
  NCT06081543 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Columbus
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
  NCT07288398 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Ohio: Cleveland, Columbus
• Left vs Left Randomized Clinical Trial
  NCT05650658 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• Longitudinal Validation of CIRC Technologies
  NCT07081711 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
  NCT01757730 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• NORM-HF Pivotal Study
  NCT07574593 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
  NCT06311708 · Phase: Not specified · Ages: 14 Years to 65 Years · Sex: All (male and female) · Ohio: Cleveland
• Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation
  NCT07436299 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
  NCT06228924 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cleveland
• PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
  NCT05934487 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  NCT04278404 · Phase: Not specified · Ages: 0 Years to 20 Years · Sex: All (male and female) · Ohio: Cincinnati
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Beavercreek, Canton, Cincinnati, Columbus
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Ohio: Akron, Cincinnati, Cleveland, Columbus
• REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
  NCT06777368 · Phase: Not specified · Ages: 18 Years to 105 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus
• Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
  NCT07069738 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
  NCT04191681 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
  NCT05919342 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
  NCT07131631 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• Simulation Trial of Telemedical Support for Paramedics
  NCT06441760 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
  NCT06217302 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cleveland
• Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
  NCT02901184 · Phase: Phase 3 · Ages: 50 Years to 99 Years · Sex: All (male and female) · Ohio: Cincinnati
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
  NCT06736574 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Marion, Sandusky
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Ohio: Cincinnati, Dayton, Maumee, Springfield
• TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
  NCT06137807 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland, Columbus
• The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
  NCT05427370 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
  NCT03142152 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland, Columbus, Dayton
• Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
  NCT06526195 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
  NCT06641362 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
  NCT05459233 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• Wearable Technology in Heart Failure Patients
  NCT07650669 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · Ohio: Cleveland